Qilian International Holding Group Limited (QLI): Price and Financial Metrics
GET POWR RATINGS... FREE!
QLI Stock Summary
- QLI has a market capitalization of $61,490,000 -- more than approximately only 10.75% of US stocks.
- QLI's went public 1.21 years ago, making it older than merely 1.18% of listed US stocks we're tracking.
- The price/operating cash flow metric for Qilian International Holding Group Ltd is higher than 97.37% of stocks in our set with a positive cash flow.
- Stocks that are quantitatively similar to QLI, based on their financial statements, market capitalization, and price volatility, are HFFG, EVK, VSH, BSET, and HLG.
- To check out Qilian International Holding Group Ltd's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001779578.
QLI Valuation Summary
- In comparison to the median Healthcare stock, QLI's EV/EBIT ratio is 20.82% lower, now standing at 23.2.
- Over the past 33 weeks, QLI's price/earnings ratio has gone down 36.5.
- Over the past 33 weeks, QLI's price/sales ratio has gone down 4.6.
Below are key valuation metrics over time for QLI.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| QLI | 2021-08-31 | 3.0 | 5.7 | 29.1 | 23.2 |
| QLI | 2021-08-30 | 3.0 | 5.7 | 29.2 | 23.3 |
| QLI | 2021-08-27 | 3.0 | 5.7 | 29.3 | 23.4 |
| QLI | 2021-08-26 | 2.9 | 5.6 | 28.7 | 22.8 |
| QLI | 2021-08-25 | 2.9 | 5.6 | 29.1 | 23.2 |
| QLI | 2021-08-24 | 3.0 | 5.7 | 29.5 | 23.5 |
QLI Stock Price Chart Interactive Chart >
QLI Price/Volume Stats
| Current price | $1.68 | 52-week high | $4.99 |
| Prev. close | $1.73 | 52-week low | $1.36 |
| Day low | $1.68 | Volume | 9,800 |
| Day high | $1.74 | Avg. volume | 20,487 |
| 50-day MA | $1.72 | Dividend yield | N/A |
| 200-day MA | $2.84 | Market Cap | 60.06M |
Qilian International Holding Group Limited (QLI) Company Bio
Qilian International Holding Group Limited operates as a holding company. The Company, through its subsidiaries, focuses in the research, development, and production of licorice and oxytetracycline products, medicine derivatives, sausage casings, and fertilizers. Qilian International Holding Group serves customers worldwide.
Latest QLI News From Around the Web
Below are the latest news stories about Qilian International Holding Group Ltd that investors may wish to consider to help them evaluate QLI as an investment opportunity.
Qilian International Holding Group Limited Reports Fiscal Year 2021 Financial ResultsQilian International Holding Group Limited (Nasdaq: QLI) (the "Company", "Qilian International", "we", "our" or "us"), a China-based pharmaceutical and chemical products manufacturer, today announced its unaudited financial results for the fiscal year ended September 30, 2021. |
Qilian International Holding Group Limited Receives Approval for the Sale of its Newly Developed Nitrofurantoin Enteric-coated TabletsQilian International Holding Group Limited (Nasdaq: QLI) (the "Company", "Qilian International", "we", "our" or "us"), a China-based pharmaceutical and chemical products manufacturer, today announced that the Company received approval from Gansu Provincial Drug Administration on January 14, 2022 for the sale of its newly developed nitrofurantoin enteric-coated tablets. This indicates that the Company officially become the first enterprise in Gansu Province with the Gansu Provincial Drug Administ |
Qilian International Holding Group Limited Releases 2022 Chairman LetterQilian International Holding Group Limited (Nasdaq: QLI) (the "Company", "Qilian International", "we", "our" or "us"), a China-based pharmaceutical and chemical products manufacturer, today released a letter to shareholders from the Chairman of the Company's board of directors. |
Qilian International Holding Group Limited Announces Inclusion of Gan Di Xin® and Qilian Shan® Oxytetracycline into List for Development of Leading Enterprises with Large Varieties and Brands of Pharmaceuticals of Gansu ProvinceQilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), a China-based pharmaceutical and chemical products manufacturer, today announced that Gan Di Xin® and Qilian Shan® Oxytetracycline, products of the Company's subsidiary, Gansu Qilianshan Pharmaceutical Co., Ltd. ("Gansu QLS"), have been included in the List for Development of Leading Enterprises with Large Varieties and Brands of Pharmaceuticals of Gansu Province (the "List"). The List selects key medicines and medical dev |
Qilian International Holding Group Limited Announces Initiation of Development of New Drug for Gastric Cancer PreventionQilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), a China-based pharmaceutical and chemical products manufacturer, announced that the Company recently started, through its subsidiary Gansu Qilianshan Pharmaceutical Co., Ltd. ("Gansu QLS"), developing a new drug, Vitacoenzyme (the "Drug"), that aims to prevent gastric cancer. Currently, Gansu QLS is in the process of selecting and cultivating fungal strain. The Drug is expected to be on the market within three years. |
QLI Price Returns
| 1-mo | -4.78% |
| 3-mo | N/A |
| 6-mo | -46.67% |
| 1-year | -63.36% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -36.60% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...